Payment overview · 2025
General Payments
$1,389.90
59 reported records · 22 companies
Healthcare provider profile · identity verified
Abid Hussain, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HEMET, CA · NPI 1821157462
Verified facts
What the public records show
CMS Open Payments records show Abid Hussain, MD received $1,389.90 in general payments during 2025 across 59 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 360 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $266.84 | 19.2% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $238.77 | 17.2% | 13 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $144.09 | 10.4% | 6 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $121.60 | 8.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.87 | 4.4% | 3 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $56.00 | 4.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $55.18 | 4.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.76 | 3.9% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $50.55 | 3.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $42.53 | 3.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.81 | 2.6% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $33.77 | 2.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.78 | 2.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.45 | 2.1% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $28.79 | 2.1% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $26.36 | 1.9% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.36 | 1.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.07 | 1.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $19.26 | 1.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.25 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.62 | 1.3% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $15.19 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,389.90 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $164.50 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $144.09 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $130.53 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $121.60 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $104.78 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $95.76 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $95.76 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $84.47 | 4 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $56.00 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $55.18 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.76 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $50.55 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $42.53 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.66 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.81 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.81 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $33.77 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.78 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.78 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.45 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $28.79 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.21 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 88 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 360 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 48 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 67 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
31 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
204 | 64 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
72 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
360 | 65 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1354 | 372 |
| Metformin Hcl | Metformin Hcl | 643 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 637 | 173 |
| Levothyroxine Sodium | Levothyroxine Sodium | 607 | 147 |
| Losartan Potassium | Losartan Potassium | 594 | 149 |
| Gabapentin | Gabapentin | 538 | 138 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 465 | 138 |
| Furosemide | Furosemide | 383 | 123 |
| Omeprazole | Omeprazole | 379 | 105 |
| Lisinopril | Lisinopril | 372 | 114 |
| Ozempic | Semaglutide | 360 | 65 |
| Famotidine | Famotidine | 346 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 345 | 93 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 307 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 298 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 289 | 76 |
| Trazodone Hcl | Trazodone Hcl | 268 | 65 |
| Carvedilol | Carvedilol | 262 | 65 |
| Simvastatin | Simvastatin | 250 | 62 |
| Alendronate Sodium | Alendronate Sodium | 239 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 223 | 75 |
| Jardiance | Empagliflozin | 204 | 64 |
| Ibuprofen | Ibuprofen | 194 | 59 |
| Tramadol Hcl | Tramadol Hcl | 187 | 56 |
| Potassium Chloride | Potassium Chloride | 177 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 171 | 59 |
| Eliquis | Apixaban | 167 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 148 | 41 |
| Benazepril Hcl | Benazepril Hcl | 146 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 140 | 32 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 137 | 105 |
| Azithromycin | Azithromycin | 135 | 113 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 135 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 120 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 120 | 29 |
| Celecoxib | Celecoxib | 117 | 27 |
| Meloxicam | Meloxicam | 115 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 113 | 54 |
| Xarelto | Rivaroxaban | 111 | 28 |
| Buspirone Hcl | Buspirone Hcl | 110 | 33 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 109 | 31 |
| Clonidine Hcl | Clonidine Hcl | 107 | 25 |
| Atenolol | Atenolol | 101 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 101 | 25 |
| Alprazolam | Alprazolam | 98 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 92 | 22 |
| Baclofen | Baclofen | 90 | 23 |
| Sertraline Hcl | Sertraline Hcl | 90 | 21 |
| Enalapril Maleate | Enalapril Maleate | 89 | 26 |
| Farxiga | Dapagliflozin Propanediol | 88 | 30 |
| Montelukast Sodium | Montelukast Sodium | 85 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 85 | 18 |
| Levetiracetam | Levetiracetam | 84 | 15 |
| Myrbetriq | Mirabegron | 80 | 11 |
| Prednisone | Prednisone | 78 | 44 |
| Allopurinol | Allopurinol | 72 | 22 |
| Glipizide | Glipizide | 72 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 72 | 14 |
| Trulicity | Dulaglutide | 72 | 19 |
| Lorazepam | Lorazepam | 69 | 17 |
| Januvia | Sitagliptin Phosphate | 68 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 68 | 13 |
| Donepezil Hcl | Donepezil Hcl | 67 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 17 |
| Invokana | Canagliflozin | 66 | 15 |
| Mirtazapine | Mirtazapine | 65 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | suppressed |
| Lovastatin | Lovastatin | 61 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 59 | 17 |
| Raloxifene Hcl | Raloxifene Hcl | 59 | suppressed |
| Spironolactone | Spironolactone | 59 | 20 |
| Entresto | Sacubitril/Valsartan | 58 | 19 |
| Nystatin | Nystatin | 56 | 23 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 54 | suppressed |
| Finasteride | Finasteride | 53 | 11 |
| Propranolol Hcl | Propranolol Hcl | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 52 | 15 |
| Ezetimibe | Ezetimibe | 52 | 18 |
| Ketoconazole | Ketoconazole | 51 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 50 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 50 | 14 |
| Olanzapine | Olanzapine | 50 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 16 |
| Pregabalin | Pregabalin | 49 | 17 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 17 |
| Rybelsus | Semaglutide | 48 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 47 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | 14 |
| Levofloxacin | Levofloxacin | 47 | 42 |
| Risperidone | Risperidone | 47 | suppressed |
| Aripiprazole | Aripiprazole | 46 | 11 |
| Nitroglycerin | Nitroglycerin | 46 | 21 |
| Meclizine Hcl | Meclizine Hcl | 45 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 12 |
| Glimepiride | Glimepiride | 44 | suppressed |
| Lidocaine | Lidocaine | 44 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 37 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 16 |
| Sildenafil Citrate | Sildenafil Citrate | 42 | suppressed |
| Temazepam | Temazepam | 42 | suppressed |
| Methocarbamol | Methocarbamol | 41 | suppressed |
| Novolog Flexpen | Insulin Aspart | 41 | 16 |
| Divalproex Sodium | Divalproex Sodium | 40 | 11 |
| Mounjaro | Tirzepatide | 40 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 39 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | 12 |
| Alcohol Pads | Alcohol Antiseptic Pads | 37 | suppressed |
| Amoxicillin | Amoxicillin | 37 | 30 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 24 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 36 | 15 |
| Linzess | Linaclotide | 35 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 33 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Prolia | Denosumab | 31 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | 11 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 30 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 30 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 25 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Folic Acid | Folic Acid | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Naproxen | Naproxen | 24 | 11 |
| Topiramate | Topiramate | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Lactulose | Lactulose | 20 | 11 |
| Lacosamide | Lacosamide | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Azathioprine | Azathioprine | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Alogliptin | Alogliptin Benzoate | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,389.90 · 59 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, APRETUDE, ARISTADA, AUSTEDO XR, BREZTRI, CAPLYTA, Cologuard Collection Kit, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), FARXIGA, FREESTYLE LIBRE 3, Fetroja, GEMTESA, JOURNAVX, Korlym, LYBALVI, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, WATCHMAN FLX, Wegovy, XIFAXAN, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error